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A B S T R A C T
Purpose
Overall survival (OS) is the deﬁnitive and best-established primary efﬁcacy end point to evaluate
diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end
point assessed post-treatment would expedite clinical trial conduct and accelerate patient access to
effective new therapies. Our objective was to formally evaluate progression-free survival (PFS) and
PFS at 24 months (PFS24) as surrogate end points for OS in ﬁrst-line DLBCL.
Patients and Methods
Individual patient datawere analyzed from 7,507 patients from 13multicenter randomized controlled
trials of active treatment in previously untreated DLBCL, published after 2002, with sufﬁcient PFS
data to predict treatment effects on OS. Trial-level surrogacy examining the correlation of treatment
effect estimates of PFS/PFS24 and OS was evaluated using both linear regression (R2WLS) and
Copula bivariable (R2Copula) models. Prespeciﬁed criteria for surrogacy required either R
2
WLS or
R2Copula $ 0.80 and neither , 0.7, with lower-bound 95% CI . 0.60.
Results
Trial-level surrogacy for PFS was strong (R2WLS = 0.83; R
2
Copula = 0.85) andmet the predeﬁned criteria
for surrogacy. At the patient level, PFS strongly correlated with OS. The surrogate threshold effect
had a hazard ratio of 0.89. Surrogacy was consistent across comparisons with or without rituximab
and with rituximab maintenance trials. Trial-level surrogacy for PFS24 was relatively strong (R2WLS =
0.77; R2Copula = 0.78) but did not meet prespeciﬁed criteria. At the patient level, PFS24 signiﬁcantly
correlated with OS. The surrogate threshold effect had an odds ratio of 1.51.
Conclusion
This large pooled analysis of individual patient data supports PFS as a surrogate end point for OS in
future randomized controlled trials evaluating chemoimmunotherapy in DLBCL. Use of this end
point may expedite therapeutic development with the intent of bringing novel therapies to this
patient population years before OS results are mature.
J Clin Oncol 36:2593-2602. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) accounts
for approximately 32% of non-Hodgkin lymphoma
(NHL) diagnoses.1 The addition of rituximab to
cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) as initial therapy for
DLBCLwas one of the key contributors to improved
5-year standardized cancer-speciﬁc survival from
52% in 1999 to 66% in 20052 and led to R-CHOP
becoming the most common ﬁrst-line treatment.
Relative 10-year survival for patients with DLBCL is
approximately 50%,1 illustrating the persisting need
for improved therapies. However, no regimen has
demonstrated a survival beneﬁt compared with
R-CHOP in a randomized trial.3-5 Approximately
10% to 15% of patients with DLBCL have disease
that is refractory to initial therapy, and another 20%
to 25% who experience relapse after an initial
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response to treatment will experience worse outcomes.6,7 Ten-year
DLBCL-speciﬁc survival is considerably dependent on the extent of
disease and prognostic score and has been shown to be 80% for
patients with low-risk, 60% for those with intermediate-risk, and 36%
for those with high-risk disease.8 Genomic tools for risk stratiﬁcation
and molecular surveillance of DLBCL have been presented,9,10 but
neither these tools nor novel agents have improved patient outcomes.
Overall survival (OS) is the gold-standard primary efﬁcacy
end point for clinical trials of antilymphoma treatment. On the
basis of studies evaluated here, it may take . 8 years to achieve
median OS for ﬁrst-line DLBCL and, depending on accrual time,
approximately 10 years to complete phase III trials using OS as an
end point. For example, a randomized controlled trial (RCT)
comparing R-CHOP with an alternative dose-intensive regimen
(CALGB [Cancer and Leukemia Group B]/Alliance 50303) opened
in 2005 and reported initial ﬁndings in December 2016.5 Results
from previous studies in DLBCL and other aggressive types of NHL
suggest that progression-free survival (PFS) and short-term out-
comes, including event-free survival and PFS at 0.5, 2, or 3 years,
should be explored as candidates for an earlier surrogate end point
for OS.11-14 However, these studies were based on suboptimal data
and/or validation methods.
We established the Surrogate Endpoints for Aggressive
Lymphoma (SEAL) international collaboration to construct a large
database integrating individual patient data (IPD) from completed,
published, multicenter RCTs in DLBCL to evaluate potential sur-
rogate end points for OS in DLBCL trials and support continuous
translational research (eg, prognostic analyses, risk classiﬁcations,
subgroup analyses).15 Several studies have been successful in using
metadatabases to provide a strong foundation and methodology for
establishing statistical criteria that assesses clinically meaningful
relationships between end points and surrogates. These studies
combined IPD frommultiple studies to identify earlier surrogate end
points for adjuvant treatment in colorectal cancer (ACCENT
[Adjuvant Colon Cancer End Points]),16 metastatic colorectal cancer
(ARCAD [Analysis and Research in Cancers of the Digestive Sys-
tem]),17 and follicular lymphoma (FLASH [Follicular Lymphoma
Analysis of Surrogate Hypothesis]).18 The speciﬁc objectives of the
SEAL study are to determine trial-level (primary) and patient-level
(secondary) correlations between two surrogate end point candi-
dates, PFS and PFS at 24 months (PFS24), with OS after ﬁrst-line
treatment of DLBCL using well-established statistical methods on
IPD. Here we report results of an analysis of data from 13 studies in
a total of 7,507 patients.
PATIENTS AND METHODS
Trial Selection and Comparison Definition
On June 30, 2015, we used the search terms DLBCL, NHL, and
aggressive or advanced or diffuse histiocytic in the title and keywords up-
front or ﬁrst-line or untreated or newly diagnosed or initial/primary/
treatment/therapy or no prior therapy or naı¨ve to conduct a compre-
hensive search of published DLBCL clinical studies in theMedline database
maintained by the US National Library of Medicine. To be included,
studies were required to be multicenter RCTs published in English from
2002 to October 13, 2015, and designed to evaluate active treatment in
$ 100 adult (no pediatric) patients with previously untreated DLBCL or
aggressive NHL deﬁned byWHO/Revised European American Lymphoma
classiﬁcation. Studies were excluded if they were reviews; if they enrolled
patients with early-stage (I or II) disease only, low-grade or indolent or
HIV-related lymphoma, or relapsed or refractory disease; or if the in-
tervention focused on salvage treatment or supportive care, such as growth
factors, palliative care, quality of life, or health economics.
The sponsors of all identiﬁed studies meeting the prespeciﬁed in-
clusion criteria were contacted to determine their interest in conﬁdentially
sharing IPD. Studies unable to transfer IPD before December 2016 were
excluded for this analysis. All exclusions were based only on data quality
and availability and were determined before any statistical analysis of the
end points.
As of August 2016, 13 of 14 studies collected in the SEAL database
met all of the inclusion criteria. Among those studies, there were 10 studies
comparing induction treatments only, two studies comparing both in-
duction and maintenance treatments, and one study comparing main-
tenance treatments only. One study19 (RICOVER60 [Rituximab With
CHOP Over Age 60 Years]) included three experimental arms compared
with one control arm. The meta-analytic unit for surrogacy estimation was
predeﬁned as the comparison between two arms (experimental v control)
nested within trials. The induction and maintenance comparisons within
the same study were treated as two comparison units. As such, a total of 17
comparison units were predeﬁned (Table 1).
Surrogate End Point Candidates
Potential surrogate candidates for OS included PFS and PFS24. PFSwas
a time-to-event end point deﬁned as the time from initiation of induction
treatment to the earliest occurrence of progressive disease, relapse, or death
resulting from any cause. Living patients without documented disease
progression were censored on the date of their last disease evaluation. PFS24
was a binary end point where patients who were alive and in disease-free
status up to 24 months after initiation of induction treatment were con-
sidered a success. The primary end point and surrogate candidates were
derived according to consistent calculation rules across studies.
Statistical Methods
True end point. The primary clinical end point was OS, deﬁned as
time from initiation of induction treatment to death resulting from any
cause. Living patients were censored on the date when they were last
documented as alive.
General statistical methods. Within-trial treatment effects for time-
to-event end points OS and PFS were quantiﬁed using hazard ratios (HRs).
Within-trial treatment effects for the binary end point PFS24 were
quantiﬁed using odds ratios (ORs), and 95% CIs were calculated for each.
Analyses were performed by using SAS software (version 9.4; SAS Institute,
Cary, NC) and R software (version 2.14; R Foundation for Statistical
Computing, Vienna, Austria).
Surrogacy evaluation. The primary surrogacy evaluation method was
trial-level surrogacy, which measured how precisely treatment effect on the
true end point may be predicted based on observed treatment effects on the
surrogate end point. At the trial level, two commonly used trial-level sur-
rogacy measures were considered: Copula bivariable (R2Copula)
35,36 and linear
regression based on weighted least squares regression method (R2WLS),
16,37
where R2Copula takes into account patient-level correlation between the two
end points and R2WLS does not. After publication of surrogacy qualiﬁcation
criteria established in the follicular lymphoma setting,18 the predeﬁned rule
for declaring trial-level surrogacy required either R2WLS or R
2
Copula $ 0.80,
with the lower boundary of a 95% CI of. 0.6, and neither estimate , 0.7.
Supplemental trial-level surrogacy measures included the sur-
rogate threshold effect,38 the minimum treatment effect on the sur-
rogate required to conﬁdently predict a signiﬁcant treatment effect on
OS in a future trial. For patient-level surrogacy, the correlations be-
tween the candidate surrogate end point and OS were quantiﬁed
through rank correlation coefﬁcient (r) for PFS via the bivariable
Clayton Copula model36; for PFS24, the global OR for comparing the
odds of remaining alive beyond a particular time point between
2594 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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patients with different PFS24 status was estimated through the
bivariable Plackett Copula model35 over the entire duration of OS.
Patient-level correlation was considered a supportive but not sufﬁcient
condition for surrogacy validation. r closer to 1.0 indicated a stronger
correlation. For the global OR, a 95% CI excluding 1 indicated sig-
niﬁcant individual-level correlation.
Sensitivity and Subpopulation Analysis
Leave-one-out cross-validation, which compares the predicted log
(HR) values with the observed values on OS based on the estimated trial-
level model, leaving one trial out at a time, assessed the predictive per-
formance of the regression model. Leave-one-out estimation, which re-
estimated R2 when one trial was excluded at a time, was performed to
identify potentially inﬂuential trials. Surrogacy was further examined
within subpopulations deﬁned by treatment type (ie, comparisons with
rituximab, induction comparisons only).
RESULTS
Patient Characteristics
Of a total of 267 references individually examined, 14 studies
were included in the SEAL database and 13 studies met all in-
clusion criteria (Fig 1). Table 1 summarizes trial-level character-
istics of the 13 studies included,19,20-34 involving IPD from 7,507
patients and 17 two-arm comparisons, of which 14 compared
Table 1. Trial Characteristics of Comparisons Included in the Analysis (n = 17)
Study Reference Study Identiﬁer Start of Accrual
Induction or
Maintenance
Included
Rituximab? Arm No. of Patients* Treatment
Merli20 (2012) ANZINTER3 2003 Induction Yes Control 110 R-CHOP21
NCT01148446 Experimental 114 R-MiniCEOP
Habermann21 (2006) E4494_1 1998 Induction Yes Control 279 CHOP21
Experimental 267 R-CHOP21
NCT00003150 E4494_2 Maintenance Yes Control 178 Observation
Experimental 174 Rituximab
Re´cher22 (2011) LNH032B 2003 Induction Yes Control 183 R-CHOP21
NCT00140595 Experimental 196 R-ACVBP
Delarue23 (2013) LNH036B 2003 Induction Yes Control 296 R-CHOP21
NCT00144755 Experimental 304 R-CHOP14
Haioun24 (2009) LNH983_1 1999 Induction No Control 239 ACVBP
Experimental 235 ACE
NCT00169169 LNH983_2 Maintenance Yes Control 131 Observation
Experimental 140 Rituximab
Coifﬁer25 (2002) LNH985 1998 Induction Yes Control 197 CHOP21
Feugier26 (2005)† Experimental 202 R-CHOP21
Coifﬁer27 (2010)
Seymour28 (2014) MAIN 2007 Induction Yes Control 379 R-CHOP (14/21)
NCT00486759 Experimental 369 RA-CHOP (14/21)
Schmitz29 (2012) MEGACHOEP 2003 Induction Yes Control 130 R-CHOEP14
NCT00129090 Experimental 131 R-MegaCHOEP
Pfreundschuh30,31
(2006 and 2011)
MInT 2000 Induction Yes Control 393 CHOP-like
NCT00064116 Experimental 403 R-CHOP-like
Jaeger32 (2015) NHL13 2004 Maintenance Yes Control 343 Observation
NCT00400478 Experimental 338 Rituximab
Herbrecht33 (2013) PIX203 2005 Induction Yes Control 62 R-CHOP21
NCT00268853 Experimental 60 R-CPOP
Pfreundschuh19
(2008)
RICOVER60_1 2000 Induction No Control 306 6 cycles CHOP14
Experimental 303 8 cycles CHOP14
NCT00052936 RICOVER60_2 Induction Yes Control 306 6 cycles CHOP14
Experimental 304 6 cycles
R-CHOP14
RICOVER60_3 Induction Yes Control 306 6 cycles CHOP14
Experimental 302 8 cycles
R-CHOP14
Cunningham34 (2013) RCHOP14v21 2005 Induction Yes Control 533 R-CHOP21
ISRCTN 16017947 Experimental 529 R-CHOP14
Abbreviations: ACE, doxorubicin, cyclophosphamide, and etoposide; ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; ANZINTER,
Intergruppo Italiano Linfomi; CEOP, cyclophosphamide, epirubicin, vincristine, and prednisone; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, and
prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; MInT, MabThera International Trial Group; NHL, non-Hodgkin lymphoma; PIX, pix-
antrone; R, rituximab.
*Sample size within each comparison. E4494 and LNH983: the patients included in the maintenance comparison were the subset of the patients included in induction
comparison who achieved complete or partial response after induction treatment. RICOVER60: the patients receiving six cycles of CHOP14 were duplicated to serve as
control arms for the other three treatment arms. The data received for analysis in this publication may vary from the original sample sizes reported in the primary
publication.
†The three reports correspond to the same study: LNH98-5. This system did not exist in 1998 when the study was designed, nor in 2002 when it was published in New
England Journal of Medicine. Later, both Journal of Clinical Oncology and Blood accepted it for publication without a number because it consisted of only follow-up
analyses. Therefore, there is no number or reference in ClinicalTrials.gov for this study, and it is not in the database of ClinicalTrials.gov.
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induction regimens and three compared maintenance regimens.
Fifteen comparisons involved rituximab.
Baseline characteristics were well balanced between arms
(Table 2), with a median age of 62.8 years; 42% of patients were
age , 60 years, 32% were age 60 to 69 years, and 26% were $ 70
years; 54% were men, and 14% had Eastern Cooperative Oncology
Group performance status $ 2. One third of patients (33%) had
International Prognostic Index (IPI) scores of 0 to 1; 25%, IPI 2;
24%, IPI 3; and 17%, IPI 4 to 5. Ann Arbor stage was I/II in 36% of
patients, III in 24%, and IV in 40%. Overall, the median follow-up
time for OS was 52 months. The distributions of PFS and OS in
overall population pooling all patients across studies are shown in
Appendix Figures A1A and A1B (online only).
PFS: Trial- and Patient-Level Surrogacy Measures
As summarized in Table 3 and Figure 2A, trial-level surrogacy
for PFS was strong (R2WLS = 0.83; 95% CI, 0.57 to 0.94; R
2
Copula =
0.85; 95% CI, 0.73 to 0.98) and met the predeﬁned criteria for
surrogacy. This implies a strong prediction of treatment effect on
OS based on observed treatment effect on PFS. The patient-level
correlation between PFS and OS considering the entire duration of
follow-up was strong, with a rank correlation coefﬁcient r of 0.85
(95% CI, 0.84 to 0.86; Table 3). The surrogate threshold effect had
anHR of 0.89, which indicated that an observed HR# 0.89 for PFS
would predict a signiﬁcant treatment effect on OS in a future trial.
Surrogacy was consistent across comparisons with and without
rituximab induction and with rituximab maintenance.
Leave-one-out cross-validation demonstrated consistency
between observed and predicted OS treatment effects for each
comparison unit on the basis of PFS (Fig 2B), except when leaving
one comparison (PIX203) out. This comparison was also shown to
be a high inﬂuence outlier when evaluating the re-estimated R2
when one comparison at a time was excluded (Fig 2C). Exclusion
of this comparison yielded an R2WLS of 0.87 (95% CI, 0.70 to 0.95)
and R2Copula of 0.88 (95% CI, 0.76 to 0.99).
PFS24: Trial- and Patient-Level Surrogacy Measures
As summarized in Table 3 and Figure 3A, trial-level sur-
rogacy for PFS24 (R2WLS = 0.77; 95% CI, 0.51 to 0.92; R
2
Copula =
0.78; 95% CI, 0.59 to 0.96) was slightly less robust than PFS and
did not meet the prespeciﬁed surrogacy qualiﬁcation criteria.
At the patient level, the global OR was 61.1 (95% CI, 52.6 to
69.6), which indicates substantially higher odds of remaining
alive beyond a particular time point for patients who were alive
and disease free at 24 months after initiation of induction
treatment (Table 3). The surrogate threshold effect had an OR
of 1.51, which indicated that an observed OR $ 1.51 for PFS24
would predict a signiﬁcant treatment effect on OS in a future
trial. Surrogacy performance improved when restricted to
References identified
(N = 267)
Considered eligible; owners contacted (n = 16)
Provided IPD; included in SEAL database (n = 14)
Included in surrogacy evaluation
Total patients
Two-arm comparison
Induction
Maintenance
Excluded/did not meet ≥ one 
inclusion criterion
Excluded by steering committee; 
end points difficult to interpret
Did not provide IPD
Excluded from surrogacy analysis; 
enrolled early-stage (I or II) 
disease only
(n = 251)
(n = 1)
(n = 1)
(n = 1)
(n = 13)
(N = 7,507)
(n = 17)
(n = 14)
(n = 3)
Fig 1. Flowchart of study selection. Abbreviation: IPD, individual patient data.
Table 2. Patient Characteristics Based on Trials Included in the Primary
Analysis (n = 13)
Characteristic
No. (%)
P
Control
(n = 3,450)
Experimental
(n = 4,057)
Total
(N = 7,507)
Age (continuous), years , .001
Mean 58.6 60.0 59.3
SD 14.7 14.2 14.4
Median 62.0 63.0 62.8
Range 18.0-89.6 18.0-92.2 18.0-92.2
Age (categorical), years , .001
, 60 1,566 (45) 1,562 (39) 3,128 (42)
60-69 1,034 (30) 1,386 (34) 2,420 (32)
$ 70 850 (25) 1,109 (27) 1,959 (26)
Sex .4172
Female 1,580 (46) 1,896 (47) 3,476 (46)
Male 1,870 (54) 2,161 (53) 4,031 (54)
ECOG PS .1988
Missing 3 1 4
0 1,627 (47) 1,837 (45) 3,464 (46)
1 1,328 (38) 1,641 (40) 2,969 (40)
$ 2 492 (14) 578 (14) 1,070 (14)
IPI score* .1476
Missing 393 384 777
0-1 1,022 (33) 1,217 (33) 2,239 (33)
2 734 (24) 968 (26) 1,702 (25)
3 768 (25) 878 (24) 1,646 (24)
4-5 533 (17) 610 (17) 1,143 (17)
Ann Arbor stage .0038
Missing 14 9 23
I/II 1,223 (35) 1,492 (37) 2,715 (36)
III 787 (23) 1,022 (25) 1,809 (24)
IV 1,426 (41) 1,534 (38) 2,960 (40)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; IPI, International Prognostic Index; SD, standard deviation.
*Percentageswere calculatedwithin each group after subtraction ofmissing IPI
score data.
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induction comparisons. Sensitivity analyses showed similar
results (Figs 3B and 3C).
DISCUSSION
This pooled analysis compiled IPD from 13 DLBCL RCTs pub-
lished from 2002 to 2015. The acquisition and integration of IPD
from these trials were conducted by an independent data center at
Mayo Clinic according to predeﬁned end point derivations and
statistical plans. The SEAL group, which conducted these analyses,
included involvement from international lymphoma experts and
biostatisticians who had previously developed these statistical
approaches in consultation with regulatory agencies from the
United States and Europe. To our knowledge, this is the ﬁrst
analysis based on integrated IPD from RCTs involving patients
with DLBCL. Unlike literature-based meta-analyses, use of IPD
ensured the consistent determination of end points and the
consistent interpretation of within-trial treatment effects across all
studies. Our analysis demonstrates that treatment effect on PFS is
a strong predictor of treatment effect on OS. These results were
consistent across different surrogacy estimation methods and
sensitivity analyses. The strong association between PFS and OS
was maintained irrespective of the inclusion of rituximab in the
induction and/or maintenance regimen. Together, these results
indicate that PFS serves as a strong surrogate for OS in trials
evaluating ﬁrst-line therapy for DLBCL.
DLBCL is the most prevalent aggressive form of NHL and
a heterogeneous disease with subtypes distinguishable by molecular,
immunophenotypic, morphologic, and clinical characteristics.39 In
the prerituximab era, the chemotherapy combination CHOP was
established as standard ﬁrst-line treatment of DLBCL based on results
from a randomized study comparing CHOP with three other more
aggressive combination chemotherapy regimens.40 Integration of the
monoclonal anti-CD20 antibody rituximab into chemotherapy reg-
imens was one of the most important advances in the treatment of
DLBCL based on data ﬁrst published in 200220 and conﬁrmed in
subsequent trials.23,24 Despite promising data from early-phase
clinical trials, since 2002, no regimen has demonstrated signiﬁcant
clinical beneﬁt over R-CHOP in a randomized controlled clinical trial.
Surrogate end points such as PFS are needed to reduce the evaluation
time for new agents and regimens so that effective ﬁrst-line regimens
and strategies can be delivered in clinical practice sooner, and in-
effective regimens can be abandoned without prolonged evaluation.
Current approaches for improving outcomes in DLBCL focus
on addressing therapeutic targets present in nearly all patients with
DLBCL, such as CD19 and CD79b, and characterizing the genetic
mutations and pathways involved in DLBCL along with their
functional roles to deﬁne risk stratiﬁcation models and identify
new therapeutic targets. Clinically, patients with DLBCL who
achieve event-free survival at 24 months after initiation of therapy
experience survival similar to that of matched controls, whereas
those who do not have poor expected survival.12 Targeting poor-
risk patients identiﬁed by clinical or genetic factors has become
a priority for deﬁning patient groups, where improving upon
outcomes with R-CHOP is needed and feasible in a suitable
timeframe for drug development. Recognition and continued
investigation into the complexity and heterogeneity of DLBCL led
to classiﬁcations based on immunohistochemistry and gene ex-
pression proﬁling that distinguish two major subtypes of DLBCL:
germinal center B cell–like DLBCL and activated B cell–like
DLBCL, with the latter type being associated with worse prognosis
in some41-45 but not all studies.46 Fluorescence in situ hybrid-
ization and immunohistochemistry also differentiate patients with
DLBCL who are positive for MYC and BCL2 and/or BCL6; these
patients experience worse outcomes when treated with R-CHOP.47,48
Precision medicine approaches that performDLBCL subtyping in all
patients and then add a novel agent to R-CHOP therapy for a poor-
risk subgroup have been projected to provide beneﬁts that outweigh
their costs,49 but at present, such strategies have failed to demonstrate
clinical beneﬁt. Three RCTs demonstrated that substituting borte-
zomib for vincristine or adding bortezomib to R-CHOP did not
signiﬁcantly improve outcomes.3,50,51 A randomized trial substituting
obinutuzumab for rituximab demonstrated that this regimen did
not signiﬁcantly improve investigator-assessed PFS compared with
R-CHOP.4 Likewise, altering the administration of R-CHOP to every
14 days instead of every 21 days increased toxicity without providing
beneﬁts.30,31 Failure of these trials has been attributed to selection bias,
leading to prospectively enrolled patients with DLBCL who had more
favorable survival thanwas expected with R-CHOP based on historical
controls, and limited additive beneﬁts of these approaches. These trials
also reinforce the use of PFS in the clinical research community as an
acceptable surrogate for OS. Novel agents and approaches are
emerging from early phase I/II clinical trials that may improve survival
Table 3. Trial- and Patient-Level Surrogacy Measures
Outcome No. of Trials (No. of patients)
Trial-Level Surrogacy Patient-Level Surrogacy
R2WLS (95% CI) R
2
Copula (95% CI) r/Global OR* (95% CI)
PFS (time-to-event end point)
Overall 17 (7,507) 0.83 (0.57 to 0.94) 0.85 (0.73 to 0.98) 0.85 (0.84 to 0.86)
Comparisons with rituximab 15 (7,001) 0.81 (0.55 to 0.93) 0.86(0.72 to 0.99) 0.86 (0.85 to 0.87)
Induction comparisons only 14 (6,826) 0.85(0.57 to 0.96) 0.88 (0.76 to 1.00) 0.86 (0.85 to 0.86)
PFS24 (binary end point)
Overall 17 (6,882) 0.77 (0.51 to 0.92) 0.78 (0.59 to 0.96) 61.1 (52.6 to 69.6)
Comparisons with rituximab 15 (6,180) 0.75 (0.45 to 0.91) 0.78 (0.59 to 0.98) 63.7 (54.0 to 73.4)
Induction comparisons only 14 (6,047) 0.80 (0.53 to 0.94) 0.82 (0.66 to 0.99) 64.1 (54.5 to 73.8)
Abbreviations: OR, odds ratio; PFS, progression-free survival; PFS24, PFS at 24 hours; WLS, weighted least squares.
*r for PFS and global OR for PFS24. r is the rank correlation coefﬁcient quantifying the individual-level correlation between PFS and OS; r closer to 1.0 indicated
a stronger correlation. Global OR quantiﬁes the individual-level correlation between PFS24 and OS. A 95%CI excluding 1 indicated signiﬁcant individual-level correlation.
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Fig 2. (A) Trial-level treatment effect correlation
between progression-free survival (PFS) and
overall survival (OS). Circle/triangle size is pro-
portional to sample size. Solid line indicates ﬁtted
weighted least squares (WLS) regression line;
gray dashed lines indicate 95% prediction limits.
(B) PFS surrogacy sensitivity analysis: leave-one-
out cross-validation. For each comparison, the
open circle/triangle is the predicted log (hazard
ratio [HR]) on OS based on the estimated WLS
regression line at trial level, removing the com-
parison listed; the horizontal bars indicate 95%
prediction interval. (C) PFS surrogacy sensitivity
analysis: leave-one-out re-estimation. For each
labeled comparison, R2WLS and R
2
Copula were es-
timated by excluding the labeled comparison;
vertical bars indicate 95% CI. ANZINTER, Inter-
gruppo Italiano Linfomi; MegaCHOEP, cyclophos-
phamide, doxorubicin, vincristine, and prednisone
plus etoposide; MInT, MabThera International Trial
Group; NHL, non-Hodgkin lymphoma; PIX, pixan-
trone; R-CHOP, rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone.
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Fig 3. (A) Trial-level treatment effect correlation
between progression-free survival at 24 months
(PFS24) and overall survival (OS). Circle/triangle
size is proportional to sample size. Solid line in-
dicates ﬁtted weighted least squares (WLS) re-
gression line; gray dashed lines indicate 95%
prediction limits. (B) PFS24 surrogacy sensitivity
analysis: leave-one-out cross-validation. For each
comparison, the open circle/triangle is the pre-
dicted log (hazard ratio [HR]) on OS based on the
estimated WLS regression line at trial level, re-
moving the comparison listed; horizontal bars
indicate 95% prediction interval. (C) PFS24 sur-
rogacy sensitivity analysis: leave-one-out re-estimation.
For each labeled comparison, R2WLS and R
2
Copula
were estimated by excluding the labeled com-
parison; vertical bars indicate 95%CI. ANZINTER,
Intergruppo Italiano Linfomi; MegaCHOEP, cyclo-
phosphamide, doxorubicin, vincristine, and predni-
sone plus etoposide; MInT, MabThera International
Trial Group; NHL, non-Hodgkin lymphoma; PIX,
pixantrone; R-CHOP, rituximab plus cyclophospha-
mide, doxorubicin, vincristine, and prednisone.
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for all patients with DLBCL, with particular attention to poor-risk
groups that may beneﬁt more from a selected therapy.52-54 Ran-
domized studies are ongoing to demonstrate the potential beneﬁt of
these approaches over R-CHOP.55,56 These trials and future studies
should examine design strategies to reduce selection bias and include
surrogate end points (such as PFS) to improve the likelihood of
success, along with reducing the time for evaluating the clinical beneﬁt
of interventions.
Future research examining PFS24 and new candidates for
surrogacy should be carried out as the SEAL collaboration con-
tinues to actively pursue additional trials and data. For emerging
novel agents substituted in or combined with R-CHOP, PFS can be
an appropriate surrogate end point when the expected mechanism
for improving OS is long-term disease control. For agents expected
to improve OS in settings where DLBCL progression is expected to
occur on treatment surrogacy, re-evaluation may be required. A
majority of clinical trials included in our analysis focused on the
induction setting. As a result, a subgroup analysis of PFS surrogacy
in the maintenance setting was not possible. As more maintenance
studies (eg, REMARC [Study of Lenalidomide Maintenance Versus
Placebo in Responding Elderly Patients With DLBCL and Treated
With R-CHOP] NCT01122472) become available to SEAL, the
surrogacy of PFS and PFS24 could be speciﬁcally tested in the
maintenance setting. Additional surrogate end point candidates in
DLBCL, such as response-based end points and event-free survival,
should be evaluated as additional data from current SEAL studies
and new studies are added.
In the ﬁrst-line setting, DLBCL treatment is administered with
the intent to achieve long-term disease control and ultimately
a cure. Although R-CHOP provides signiﬁcant clinical beneﬁts to
patients, these advantages challenge the conduct of future trials of
newer therapeutic options. More efﬁcient approaches are needed to
promote the development of novel therapies in a timely manner,
provide patients earlier access to more effective therapeutic op-
tions, and more rapidly evaluate and discard approaches that do
not have a clinically signiﬁcant impact. Establishing surrogate RCT
end points that are measured earlier than current approaches can
facilitate future drug development. The results of the SEAL analyses
have demonstrated that treatment effects on PFS strongly predicts
for treatment effects on OS. Although PFS24 was signiﬁcantly
correlated with longer OS at the patient-level analysis, it did not
meet the trial-level prespeciﬁed surrogacy qualiﬁcation criteria.
Future analyses with additional trials should re-evaluate the role of
PFS24 as a surrogate end point, focusing on the trial-level cor-
relation with OS. In conclusion, this pooled analysis of IPD from
randomized clinical trials of ﬁrst-line treatments for patients with
DLBCL demonstrates that the primary surrogate candidate, PFS,
met the qualiﬁcation criteria to be a robust surrogate end point for
OS. These results support the use of PFS as an appropriate primary
end point in future studies evaluating chemoimmunotherapy in
patients with DLBCL.
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Appendix
The following investigators, contributors, and study groups were included in the analysis: FrancescoMerli and the Intergruppo
Italiano Linfomi (ANZINTER), ThomasM. Habermann and the US Intergroup (ECOG 4494), Groupe d’Etude des Lymphomes de
l’Adulte (GELA; now LYSARC), Amgen, and Roche, along with Christian Re´cher (LNH03-2B), Richard Delarue (LNH03-6B),
Corrinne Haioun (LNH 98-3), Bertrand Coifﬁer and Pierre Feugier (LNH98-5), John F. Seymour and F. Hoffman-La Roche
(MAIN), Norbert Schmitz and the German High-Grade Lymphoma Study Group (DSHNHL 2002-1), Michael Pfreundschuh and
the MabThera International Trial Group (MInT) and Roche, Ulrich Jaeger and the Arbeitsgemeinschaft Medikamento¨se
Tumortherapie (AGMT; NHL13), Raoul Herbrecht and Cell Therapeutics (PIX203), Michael Pfreundschuh and Deutsche
Krebshilfe (RICOVER-60), and David Cunningham and Cancer Research UK (UCL).
Surrogate Endpoints for Aggressive Lymphoma (SEAL) group membership: The SEAL group (in alphabetic order) consists of:
Bertrand Coifﬁer, David Cunningham, Jocelyne Flament, Christopher R. Flowers, Tommy Fu, Herve´ Ghesquieres, Thomas M.
Habermann, Corinne Haioun, Raoul Herbrecht, Ulrich Jaeger, Matthew J. Maurer, Francesco Merli, Tina Nielsen, Fang-Shu Ou,
Michael Pfreundschuh, Daniel J. Sargent, Norbert Schmitz, John F. Seymour, Qian Shi, Herve´ Tilly, Lixia Wang, andMarita Ziepert.
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Fig A1. Distribution of (A) progression-free survival in overall population pooling of all patients across studies and (B) overall survival in overall population pooling of all
patients across studies at a median follow-up time of 52 months.
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